Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 27;29(8):2099–2109. doi: 10.1038/s41591-023-02452-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — a, Systemic inflammation following gavo-cel treatment. a, Increase in serum lactate dehydrogenase (LDH) after infusion of gavo-cel that peaked at day 9. It gradually decreased to reach normal range by day 142 (normal range: 125–220 U/mL). b, Mesothelin expression in tumor biopsy after progression. Tumor biopsy obtained after progression on day +365 shows mesothelin expression. Experiment performed once on patient samples. Inset scale bars represents 100 µM. c, Persistence of gavo-cel in peripheral blood post-infusion by flow cytometry. Flow cytometry analysis of PBMCs isolated from peripheral blood and stained with anti-VHH antibody showed 50.7% cells being TRuC+ on day 10. On day 28 this was reduced to 13.3%, whereas on day 56, 0.5% cells were detected as TRuC+. d, Phenotypic analysis of gavo-cel product. Flow-cytometric analysis of the different T cell subsets in the manufactured gavo-cel product that was infused into the patient. Phenotyping revealed a predominance of stem cell memory (T_SCM) and naïve T (T_N) cells, with the majority of the remaining T cells having a central memory T cell (T_CM) phenotype. The proportion of T_SCM and T_N was similar in the CD4+ and CD8 + T cell subsets. T_EM, T effector memory cell; T_EMRA, effector memory T cells re-expressing CD45RA.

Source data